INNATE PHARMA search results are presented at Columbia University in New-York, USA, this Friday, October 28, 2016. HISTALIM’s teams are proud of having contributed to it.
During the 3rd World Congress of Cutaneous Lymphomas (3WCCL), the first results of its Phase I trial of IPH4102, an INNATE PHARMA’s proprietary antibody, will be presented by the Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris.
The aim of this trial is to test the tolerance, the security and activity of IPH4102 for the cutaneous T-cell lymphomas (“CTCL”) treatment. It covers a population of relapsed/refractory patients, for which there are few treatment options and the prognosis is unfavorable. It is also to evaluate an associated biomarker to measure the expression of KIR3DL2 in patients, for monitoring the disease.
The IPH4102 is a humanized cytotoxic antibody “first-in-class” targeting KIR3DL2 and to kill the CTCL cells expressing the target. KIR3DL2, meanwhile, is an inhibitory receptor of the family of KIR, normally expressed on a fraction of normal NK (“Natural Killers”), but specifically expressed in all subtypes of CTCL, an orphan indication.
HISTALIM played the role of central lab in this multicenter clinical trial (Europe-USA) for the monitoring of immunohistochemical biomarkers. These markers were used for patient enrollment, monitoring of disease progression and mechanistic investigations to understand and visualize the associated phenomena.
Thanks to its secure data exchange platform, allowing the intervention of a distant expert pathologist, HISTALIM was able to make the diagnosis of inclusion in less than a week.
These encouraging results consolidate the pursuit of the trial which plans to include up to 60 patients.
INNATE PHARMA : http://innate-pharma.com/en